Abstract
Dolutegravir was recommended as first line antiretroviral therapy (ART) across all ages by WHO in 2018. At that time, no dosing data was available for children living with HIV weighing less than 15 kg and appropriate formulations were not available in high burden settings.1 There was also no evidence of superior outcomes in children living with HIV.1 With approximately 800 000 children living with HIV not receiving ART and low viral suppression rates,2 robust child friendly dolutegravir-based regimens will allow for once daily dosing, align with adult guidelines, and improve outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
